Enlivex Therapeutics (ENLV) announced the enrollment and dosing of the first 10 patients in its Phase II Allocetra trial of individuals with moderate to severe knee osteoarthritis in November. This is a double-blind, randomized, placebo-controlled study evaluating the safety and effectiveness of Allocetra injections into the knee. The pharmaceutical company notes there have been no safety concerns following the initial injections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Enlivex Therapeutics’ study has the potential to bring in a large number of new customers as osteoarthritis is one of the leading forms of adult chronic pain and long-term disability. Additionally, no commercially available drugs are proven to arrest or reverse the progression of the disease, meaning Enlivex Therapeutics could be a major player in the space if the trial meets primary endpoints.
ENLV stock is up 0.96% as of this writing and has gained 1.94% over the past three months.
